Tag - NASH


Brookline starts CohBar at buy; PT $10

Brookline Capital Markets initiated coverage of CohBar (NASDAQ:CWBR) with a “buy” rating and $10 price target. The stock closed at $2.63 on May 26. CohBar is developing CB4211, a novel and optimized analog of MOTS-c, a...

Viking Therapeutics to complete two POC trials in 2016

Viking has successfully completed three Phase 1 studies with VK5211, including a 21-day ascending dose study. Viking Therapeutics (NASDAQ:VKTX) expects to complete two proof-of-concept Phase 2 trials in 2016 in patients...